Is Lancet Oncology a Good Journal? Fit Verdict
Lancet Oncology IF 35.9, ~8-10% acceptance. Who should submit, who should target JCO or Cancer Cell instead, and why.
Associate Professor, Clinical Medicine & Public Health
Author context
Specializes in clinical and epidemiological research publishing, with direct experience preparing manuscripts for NEJM, JAMA, BMJ, and The Lancet.
Journal fit
See whether this paper looks realistic for The Lancet Oncology.
Run the Free Readiness Scan with The Lancet Oncology as your target journal and see whether this paper looks like a realistic submission.
How to read The Lancet Oncology as a target
This page should help you decide whether The Lancet Oncology belongs on the shortlist, not just whether it sounds impressive.
Question | Quick read |
|---|---|
Best for | The Lancet Oncology publishes cancer research that changes practice globally. Part of the Lancet family, it. |
Editors prioritize | Practice-changing clinical impact |
Think twice if | Submitting Phase 2 trials as practice-changing |
Typical article types | Article, Fast-Track Article, Review |
Lancet Oncology is a top-tier clinical oncology journal with a 2024 JCR impact factor of 35.9 and an acceptance rate around 8-10%. It's unambiguously a good journal. The real question is whether it's the right journal for your specific paper.
Quick answer
Lancet Oncology is excellent for practice-changing clinical oncology research with global relevance. It's the wrong target for cancer biology without clinical endpoints, early-phase trials without clear practice implications, or regional studies without global significance. If your paper could change what oncologists do for patients worldwide, Lancet Oncology is a legitimate target. If the excitement is mainly about the biology, Cancer Cell or Nature Cancer is the better home.
The numbers
Metric | Value |
|---|---|
Impact Factor (2024 JCR) | 35.9 |
Acceptance rate | ~8-10% |
Desk rejection rate | ~70-80% |
Publisher | Lancet Publishing Group (Elsevier) |
Scope | Clinical oncology with global practice relevance |
Review model | Lancet family: structured abstract, Research in Context, in-house statistical review |
Who should submit
Clinical trialists with practice-changing results. If you have a randomized trial that demonstrates a new standard of care, a survival benefit with a new agent, or a practice-changing approach to a common cancer, Lancet Oncology is a natural target.
Large-scale epidemiologists with global cancer data. Population-level studies that change how oncologists think about cancer risk, screening, or prevention at a global scale fit the journal's editorial identity.
Authors with strong Research in Context. If the Research in Context panel writes itself because the clinical implications are self-evident, the paper belongs at a Lancet journal.
Who should think twice
Cancer biologists. Lancet Oncology is not a cancer biology journal. A paper about tumor microenvironment signaling, however elegant, belongs at Cancer Cell (IF 44.5), Nature Cancer, or Cancer Discovery. The clinical endpoint needs to be real, not theoretical.
Early-phase trialists. Phase I and single-arm phase II trials rarely have the evidence level Lancet Oncology demands. JCO publishes these more readily.
Authors with regional data only. A treatment outcome study from a single institution or country needs to demonstrate why the finding matters globally. The Lancet Regional Health journals may be a better fit.
How Lancet Oncology compares
Journal | IF (2024) | What it selects for |
|---|---|---|
Lancet Oncology | 35.9 | Practice-changing clinical oncology with global relevance |
JCO | 41.9 | Broad clinical oncology (higher IF, more papers) |
Cancer Cell | 44.5 | Cancer biology and translational mechanisms |
Nature Cancer | ~23 | Cancer research bridging biology and medicine |
Cancer Discovery | 25.1 | Translational cancer science |
Annals of Oncology | 32.0 | European clinical oncology perspective |
The Lancet Oncology vs JCO comparison is the one most clinical oncologists face. JCO (IF 41.9) actually has a higher impact factor, publishes significantly more papers, and accepts a broader range of clinical oncology. Lancet Oncology (IF 35.9) is more selective and specifically emphasizes global practice change with the Lancet family's structured review process.
For many clinical oncology papers, JCO is the more practical target. Lancet Oncology is the right choice when the finding has clear global significance and the Lancet editorial style (Research in Context, concurrent statistical review) adds value.
Submit if:
- the clinical finding could change oncology treatment guidelines globally
- the evidence level is strong (randomized trial, large prospective study, definitive meta-analysis)
- the Research in Context panel makes the practice implications obvious
- you've addressed the statistical rigor the Lancet in-house team will scrutinize
Think twice if:
- the paper is cancer biology without clinical endpoints (Cancer Cell, Nature Cancer)
- JCO would reach the same audience with a less restrictive editorial process
- the finding is mainly relevant to one country or healthcare system
- the trial design has known limitations the in-house statisticians will flag
A free manuscript scan can help assess whether the clinical evidence meets Lancet Oncology's practice-changing threshold.
FAQ
Is Lancet Oncology better than JCO?
Different, not better. JCO has a higher IF (41.9 vs 35.9) and publishes more papers. Lancet Oncology is more selective and emphasizes global practice change. Many papers could go to either journal.
Is Lancet Oncology hard to get into?
Yes. Acceptance rate is ~8-10% with 70-80% desk rejection. The editorial filter is specifically about practice-changing clinical evidence.
Does Lancet Oncology publish translational work?
Rarely, and only when the translational finding has direct clinical implications with patient-level evidence. Pure translational oncology belongs elsewhere.
Sources
- Clarivate Journal Citation Reports (released June 2025)
- Lancet Oncology information for authors
Final step
See whether this paper fits The Lancet Oncology.
Run the Free Readiness Scan with The Lancet Oncology as your target journal and get a manuscript-specific fit signal before you commit.
Anthropic Privacy Partner. Zero-retention manuscript processing.
Not ready to upload yet? See sample report
Where to go next
Start here
Same journal, next question
- How to Submit to Lancet Oncology: Complete Guide
- How to Avoid Desk Rejection at Lancet Oncology
- Lancet Oncology Review Time: What to Expect From Submission to Decision
- Lancet Oncology Acceptance Rate 2026: How Selective Is It?
- Lancet Oncology Impact Factor 2026: 35.9, Rank 8/326, and What It Means
- Lancet Oncology Submission Process: What Happens After You Upload
Supporting reads
Conversion step
See whether this paper fits The Lancet Oncology.
Anthropic Privacy Partner. Zero-retention manuscript processing.